Polymer nanoparticle-based controlled pulmonary drug delivery

Methods in Molecular Biology

Volumn 1141, Issue , 2014, Pages 133-145

  Beck Broichsitter, Moritz ^a   Dalla Bona, Alexandra C ^a   Kissel, Thomas ^a   Seeger, Werner ^a   Schmehl, Thomas ^a  

^a NONE

Author keywords

Biodegradable charge modified branched polyesters; Controlled pulmonary drug delivery; Isolated lung model; Polymeric nanoparticles; Vibrating mesh nebulization

Indexed keywords

BERACTANT; NANOPARTICLE; POLYESTER;

AEROSOL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SYNTHESIS; FLUORESCENCE SPECTROSCOPY; IN VITRO STUDY; ISOLATED LUNG; LUNG MODEL; MALE; NEBULIZATION; NEBULIZER; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; ZETA POTENTIAL;

EID: 84929941878     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0363-4_8     Document Type: Chapter

References (32)

1. Courrier HM, Butz N, Vandamme TF (2002) Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 19:425–498.
2. Groneberg DA, Witt C, Wagner U et al (2003) Fundamentals of pulmonary drug delivery. Respir Med 97:382–387.
3. Gessler T, Seeger W, Schmehl T (2011) The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 5:195–206.
4. Gaspar MM, Bakowsky U, Ehrhardt C (2008) Inhaled liposomes–current strategies and future challenges. J Biomed Nanotechnol 4:245–257.
5. Kurmi BD, Kayat J, Gajbhiye V et al (2010) Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 7:781–794.
6. Azarmi S, Roa WH, Löbenberg R (2008) Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Delivery Rev 60:863–875.
7. L ebhardt T, Roesler S, Beck-Broichsitter M et al (2010) Polymeric nanocarriers for drug delivery to the lung. J Drug Delivery Sci Technol 20:171–180.
8. Beck-Broichsitter M, Merkel OM, Kissel T (2012) Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Contr Release 161:214–224.
9. Beck-Broichsitter M, Schmehl T, Gessler T et al (2012) Development of a biodegradable nanoparticle platform for sildenafil: formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. J Contr Release 157:469–477.
10. Beck-Broichsitter M, Gauss J, Packhaeuser CB et al (2009) Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int J Pharm 367:169–178.
11. Beck-Broichsitter M, Gauss J, Gessler T et al (2010) Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. J Aerosol Med 23:47–57.
12. Dailey LA, Schmehl T, Gessler T et al (2003) Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Contr Release 86:131–144.
13. Dailey LA, Kleemann E, Wittmar M et al (2003) Surfactant-free, biodegradable nanoparticles for aerosol therapy based on branched polyesters, DEAPA-PVAL-g-PLGA. Pharm Res 20:2011–2020.
14. Beck-Broichsitter M, Kleimann P, Gessler T et al (2012) Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: formulation aspects and nanoparticle stability to nebulization. Int J Pharm 422:398–408.
15. Beck-Broichsitter M, Kleimann P, Schmehl T et al (2012) Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibratingmesh nebulizers. Eur J Pharm Biopharm 82: 272–280.
16. Beck-Broichsitter M, Knuedeler MC, Schmehl T et al (2013) Following the concentration of polymeric nanoparticles during nebulization. Pharm Res 30:16–24.
17. Dailey LA, Jekel N, Fink L et al (2006) Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 215:100–108.
18. Beck-Broichsitter M, Schmehl T, Seeger W et al (2011) Evaluating the controlled release properties of inhaled nanoparticles using isolated, perfused, and ventilated lung models. J Nanomater. Article ID 163791.
19. Sakagami M (2006) In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58: 1030–1060.
20. Agu RU, Ugwoke MI (2011) In vitro and in vivo testing methods for respiratory drug delivery. Expert Opin Drug Deliv 8:57–69.
21. Nahar K, Gupta N, Gauvin R et al (2013) In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci 49: 805–818.
22. Vauthier C, Bouchemal K (2009) Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26:1025–1058.
23. Beck-Broichsitter M, Rytting E, Lebhardt T et al (2010) Preparation of nanoparticles by solvent displacement for drug delivery: a shift in the “ouzo region” upon drug loading. Eur J Pharm Sci 41:244–253.
24. D anhier F, Ansorena E, Silva JM et al (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Contr Release 161: 505–522.
25. Dailey LA, Kissel T (2005) New poly(lactic-co-glycolic acid) derivatives: modular polymers with tailored properties. Drug Discov Today: Technol 2:7–14.
26. Wittmar M, Unger F, Kissel T (2006) Biodegradable brushlike branched polyesters containing a charge-modified poly(vinyl alcohol) backbone as a platform for drug delivery systems: synthesis and characterization. Macromolecules 39:1417–1424.
27. Hofmann W (2011) Modelling inhaled particle deposition in the human lung–a review. J Aerosol Sci 42:693–724.
28. Beck-Broichsitter M, Schweiger C, Schmehl T et al (2012) Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. J Contr Release 158: 329–335.
29. Packhäuser CB, Lahnstein K, Sitterberg J et al (2009) Stabilization of aerosolizable nano-carriers by freeze-drying. Pharm Res 26:129–138.
30. Sitterberg J, Özcetin A, Ehrhardt C et al (2010) Utilising atomic force microscopy for the characterisation of nanoscale drug delivery systems. Eur J Pharm Biopharm 74:2–13.
31. Clark AR (1995) The use of laser diffraction for the evaluation of aerosol clouds generated by medical nebulizers. Int J Pharm 115:69–78.
32. Seeger W, Walmrath D, Grimminger F et al (1994) Adult respiratory distress syndrome: model systems using isolated perfused rabbit lungs. Methods Enzymol 233:549–584.